EN DE
Watch Sarepta Therapeutics Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Sarepta Therapeutics Inc (SRPT) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Sarepta Therapeutics Inc stock $15.45, price $15.13, upside +2.1%, quality 33 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US8036071004

ST Sarepta Therapeutics Inc logo Thin data Nov 17, 2026

Sarepta Therapeutics Inc

SRPT · US

The stock is already about fairly priced, weak company and price moving sideways: meets none of the 3 rules.

Get notified free when this changes
Fair value $15.45 · Fairly valued 
Price moving sideways (no uptrend) 
Mixed Growth (revenue 5y +32.4 %/yr in USD) 
Moderate debt 
Mixed vs. peers (5/12) 
Quality 33/100 
Loss-making · -5.9% net margin (TTM) 
Negative free cash flow 
Narrow moat 16/100 · thin data
Recent news mostly negative 
Thin data 
Estimate
Watch Sarepta Therapeutics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$163.85 $11.93 Fair Value $15.45 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

60‑month range $11.93 – $163.85 · fair‑value band $11.58 – $19.31 · the $15.13 price screens below the $15.45 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.

Follow Sarepta Therapeutics in your weekly email

Every Wednesday you see whether Sarepta Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases.

Show moreShow less

It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.

The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials.

It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Stock analysis

Sarepta Therapeutics Inc (SRPT) currently trades at $15.13, while our estimate is $15.45, so the stock looks roughly fairly valued today (gap 2.1%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $11.58 (bear) to $19.31 (bull), the price of $15.13 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Sarepta Therapeutics Inc reported revenue of $2.2B in FY2025 versus $702M in FY2021, a compound +33.0%/yr. Reported net income was −$713M in FY2025.

Key figures

Market cap $1.7B Small · P/S ratio 0.95 · EPS (TTM) $0.0200 · Net margin −32.5% · Return on equity −8.1% · Return on assets (EBIT) −10.8% (5-year average) · Operating margin −2.4% · Revenue (TTM) $2.0B.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (low confidence).

What moves the price

The share trades about 37% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at 2%, SRPT screens cheaper than that median.

Fair Value

Bear $11.58 Fair Value $15.45 Bull $19.31
Price $15.13 · Upside +2.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 33/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 23
How much profit the company makes from its sales and capital
Quality Growth 34
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 46
Debt, balance sheet and risk of trouble
Investment 58
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 28
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 10
Distance to the 52-week high, does not count
New shares 55
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • SaleStephen MayoDirector7,239 shares at $17.02$123,208Mar 12, 2026
  • SaleIan Michael EstepanChief Operating Officer13,187 shares at $22.31$294,202Dec 16, 2025

Plus 13 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+15.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+32.4%
Start year 2020 (pandemic)
Revenue growth 30 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−104.5% (2020) → −29.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch SRPT, get fair value alerts →

Earlier news

News mood ⓘNews mood, the average tone of recent news (95 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Negative
Recent news coverage is more negative than average.

Compare Sarepta Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks

Beats the industry median on 4/11 measures
Overall it trails its industry peers.
Valuation
Quality Score 33 · Below median
Fair Value upside +2.1% · Top 25%
Profitability
Return on assets −21.3% · Above median
Net margin (12 months) −5.9% · Below median
Operating margin (12 months) −2.4% · Below median
Growth and dividend
Revenue growth (quarter YoY) −4.5% · Below median
Balance sheet
Debt / equity 0.73× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.47× · Cheaper than median
P/S (12 months) 0.86× · Cheapest 25%
EV/EBITDA 71.8× · Priciest 25%
PEG 159.25× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)36 · sector 0
FUTURE (revenue growth)0 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)64 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs SRPT
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs SRPT
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs SRPT
argenx SE ARGX $950.95 $908.40 −4% vs SRPT
CSL Limited CSL A$199.55 A$186.49 −7% vs SRPT
Moderna, Inc MRNA $215.27 $135.64 −37% vs SRPT
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs SRPT
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs SRPT
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs SRPT
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs SRPT

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sarepta Therapeutics Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Sarepta Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/SRPT

Frequently asked questions

Is Sarepta Therapeutics Inc (SRPT) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is $15.45 versus a price of $15.13, about +2% upside (fairly valued).
What is the fair value of SRPT?
Our estimate for Sarepta Therapeutics Inc is $15.45 (as of Nov 17, 2026), built from audited fundamentals. The current price: $15.13.
What is the quality score of SRPT?
Sarepta Therapeutics Inc has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sarepta Therapeutics Inc (SRPT)?
Our calculated price target is the estimate of $15.45 (as of Nov 17, 2026). Cautious scenario $11.58, optimistic scenario $19.31. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Sarepta Therapeutics Inc stock forecast for 2026?
Our estimate puts fair value at $15.45, about +2% upside versus a price of $15.13 (fairly valued). Cautious scenario $11.58, optimistic scenario $19.31. The calculation is refreshed regularly with new filings.
What is the revenue of Sarepta Therapeutics Inc (SRPT)?
Sarepta Therapeutics Inc reported trailing-twelve-month revenue of about $2.0B (latest available figure, as of Nov 17, 2026).
What is the intrinsic value of Sarepta Therapeutics Inc (SRPT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sarepta Therapeutics Inc it is $15.45 per share (as of Nov 17, 2026), against a price of $15.13.
Is Sarepta Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 17, 2026, SRPT trades below its calculated fair value: price $15.13, fair value $15.45, a gap of about +2% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SRPT?
No. The price is what the market pays today ($15.13); the fair value is what the company's own numbers justify ($15.45). For Sarepta Therapeutics Inc the two are $0.3200 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sarepta Therapeutics Inc worth?
The market values Sarepta Therapeutics Inc at about $1.7B (market capitalisation, as of Nov 17, 2026). Per share that is $15.13; our models calculate a fair value of $15.45 per share.
What do the bullish and bearish scenarios say about SRPT?
Our models span a range for Sarepta Therapeutics Inc: cautious scenario $11.58, base $15.45, optimistic $19.31 per share (as of Nov 17, 2026, price $15.13). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of SRPT?
The PEG ratio of Sarepta Therapeutics Inc is 159.25 (P/E divided by earnings growth, as of Nov 17, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Sarepta Therapeutics Inc (SRPT)?
Balance-sheet figures for Sarepta Therapeutics Inc (as of Nov 17, 2026): return on equity −8.1%, debt of 0.73 per unit of equity. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is SRPT from its 52-week high?
Sarepta Therapeutics Inc trades at $15.13, about 37% below its 52-week high of $23.83 and 2% above the low of $14.86 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $15.45 is for.
Which stocks are comparable to Sarepta Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sarepta Therapeutics Inc stock attractive at the current price?
The data as of Nov 17, 2026: price $15.13, calculated fair value $15.45 (+2%), Quality Score 33/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Sarepta Therapeutics Inc currently trades 2% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sarepta Therapeutics Inc (SRPT)?
The closing price on Nov 16, 2026 was $15.13. Our estimate is $15.45, about +2% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sarepta Therapeutics Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Sarepta Therapeutics Inc

How large is the market capitalisation of Sarepta Therapeutics Inc (SRPT)?
The market capitalisation of Sarepta Therapeutics Inc is $1.7B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sarepta Therapeutics Inc (SRPT)?
The price-to-sales ratio of Sarepta Therapeutics Inc is 0.95 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sarepta Therapeutics Inc (SRPT)?
Earnings per share at Sarepta Therapeutics Inc are $0.0200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Sarepta Therapeutics Inc (SRPT)?
The net margin of Sarepta Therapeutics Inc is −32.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sarepta Therapeutics Inc (SRPT)?
The return on equity (ROE) of Sarepta Therapeutics Inc is −8.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sarepta Therapeutics Inc (SRPT)?
On an EBIT basis the return on assets of Sarepta Therapeutics Inc is −10.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sarepta Therapeutics Inc (SRPT)?
The operating margin of Sarepta Therapeutics Inc is −2.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sarepta Therapeutics Inc (SRPT)?
Revenue at Sarepta Therapeutics Inc is down 4.5% versus a year earlier (3y avg +33.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sarepta Therapeutics Inc (SRPT)?
Earnings per share at Sarepta Therapeutics Inc are growing 26.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Sarepta Therapeutics Inc (SRPT) generate?
The free cash flow of Sarepta Therapeutics Inc is −$307M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Sarepta Therapeutics Inc (SRPT) carry?
The net debt of Sarepta Therapeutics Inc is $238M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Sarepta Therapeutics Inc in the live analysis

One click puts Sarepta Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.